Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.05%), DAX30 (0.46%), CAC40 (0.07%)

Jun 19 ,2025

  • Synopsis

    • European equity markets are set to open in negative territory amid Asian equities trading lower Thursday with focus still largely Middle East. Losses picking up on benchmarks with Greater China, Taiwan and Japan leading declines. Korea seeing milder decline while Australia flat. S&P 500 futures retreating afterhours (US closed Thursday for holiday). JGB yields down 1-2 bp while Aussie curve bull flattening following soft jobs data. Dollar strongest against kiwi and Aussie, up slightly against majors. Crude fluctuating amid latest volley of Middle East headlines. Gold pulling back from earlier highs. Bitcoin remains rangebound.

    • Geopolitical developments in focus. President Trump held another National Security Council meeting on Wednesday after earlier saying he had idea on how to proceed but no decision made yet. Media sources noted Trump has approved plans for strike on Iran, which may happen in coming days. However, Trump waiting to see if Tehran abandons nuclear program and said to be mindful about being drawn into prolonged conflict. Prospects for diplomatic outcome remain unclear with Iran's foreign minister to hold talks with EU on Friday, while Trump said he is not looking for ceasefire but total victory.

    • In central banks updates, SNB publishes its latest Financial Stability Report at 6:30CET with interest rate decision (and news conf) at 9:30, a cut of (25bps) to 0.0% expected. Of interest, will they signal willingness to go negative rates again after June with negative inflation readings. ECB's Lagarde speeches at 9:30CET and 12:30 at conf. organised by the central banks of Poland and Ukraine (Lithuania central bank's Šimkus panellist at 13:15). Norges Bank interest rate decision at 10:00CET, with no change to 4.5% benchmark interest rate expected. ECB's Buch fireside chat at 10:30 at event hosted by Univ. of Amsterdam, the same time as Bank of France's Villeroy speaks at event at European Univ. Institute in Florence. BOE interest rate decision (Monetary Policy Summary and minutes of the MPC meeting) at 12noon BST. The expectation is for no change in the 4.25% benchmark interest rate. Bundesbank's Nagel speaks/interview/Q&A at 11:00CET and ECB's de Guindos 11:45 at OPGE conf. Bank of Italy's Signorini speech at 11:30CET at event hosted by IVASS. Turkey central bank interest rate decision at 12:00BST. A (200bps) cut to 44% in the benchmark interest rate is expected. ECB's Lagarde remarks at 18:00CET at Financi'Elles event. Denmark's central bank hosts conf on climate change and green transition - consequences for the financial sector. Eurogroup meeting takes place, ECB's Cipollone among the participants, and EU social policy council meets.

    • Macroeconomic updates include: Switzerland May trade balance (monthly watch data), Eurozone Apr construction output, Netherlands May unemployment rat

    • Amidst light earnings calendar, Addex Therapeutics (ADXN.SW) posted Q1 earnings whilst SkiStar (SKIS.B.SS) released Q3 numbers. In the UK, PS Pensions Group (XPS.LN) and NCC Group (NCC.LN) are due to report their latest numbers. Whitbread (WTB.LN) to issue Q1 trading update. On M&A front, people familiar with the process told the FT that Barclays (BARC.LN) and Santander (SAN.SM) are thinking about buying Sabadell's UK unit (SAB.SM).

    • CMD/events: United Utilities Group (UU.LN)

  • Politics/Macro/World News

    • Trump approved attack plans for Iran - but hasn't made final decision to strike - CBS News

    • EU devises scheme to squeeze more profit from Russian frozen assets - Politico

    • Why the EU's migration dilemma is pushing the bloc further right - FT

    • Hungary discussing business deal with US to counter tariff impact - Bloomberg

    • Netherlands May Unemployment Rate 3.8% vs consensus 3.7% and prior 3.8%

  • Top company news

    • Earnings/updates

      • ADXN.SW (Addex Therapeutics) -- reports Q1 net loss (CHF1.5M) vs year-ago (CHF3.1M)

      • SKIS.B.SS (SkiStar) -- reports Q3 EPS SEK3.82 vs FactSet SEK3.96 [4 est, SEK3.46-4.64]

    • M&A

      • MT.NA (ArcelorMittal) -- completes acquisition of Nippon Steel's interest in AM/NS Calvert

      • SGO.FP (Compagnie de Saint-Gobain) -- acquires Maturix in Denmark; terms undisclosed

      • STERV.FH (Stora Enso) -- initiates strategic review of Swedish forest assets

      • SAAB.B.SS (Saab) -- signs a joint declaration of intent with Direction générale de l'armement regarding the sale of Saab's GlobalEye Early Warning and Control (AEW&C) aircraft to France

      • SAB.SM (Banco de Sabadell) -- NatWest chooses not to bid for TSB - FT

      • CVC.NA (CVC Capital Partners) -- to finance Jersey Telecom's £500M bid to acquire Manx Telecom - Sky News

      • KTN.GR (Kontron) -- signs term sheet with congatec; congatec to acquire a majority stake in subsidiary JUMPtec

      • EVN.AV (EVN AG) -- and STRABAG sign transaction agreements for the sale of the international project business

      • MULTI.NO (Multiconsult) -- signs intends to acquire the ViaNova group for a transaction valued at NOK 300M on a debt and cash-free basis

      • REVB.LN (Revolution Beauty Group) -- Frasers no longer interested in Revolution Beauty Group - Telegraph

      • MAU.FP (Maurel et Prom)-- agrees to jointly acquire additional interests in Blocks 3/05 and 3/05A in Angola

    • Healthcare

      • ROG.SW (Roche Holding) -- NICE recommends Genentech's Tecentriq for adjuvant treatment of resected NSCLC

      • GLPG.NA (Galapagos) -- presents new data from cohort 3 of ATALANTA-1 for GLPG5101 in relapsed/refractory indolent NHL patients at ICML 2025

      • ZEAL.DC (Zealand Pharma) -- announces positive topline results from 28-week Phase 1B trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

      • INDV.LN (Indivior) -- SEC filing: SCHEDULE 13D/A (Filed by Two Seas Capital LP)

      • DIM.FP (Sartorius Stedim Biotech) -- Chairman Joachim Kreuzburg resigns; Michael Grosse appointed as successor

      • HNSA.SS (Hansa Biopharma) -- 10.6M-directed-share issue priced at SEK22 per share through DNB and Jefferies

    • Other

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for May

      • ETL.FP (Eutelsat Communications) -- Eutelsat and France's Armed Forces Ministry reach framework agreement for low orbit satellite services for NEXUS Program

      • TGS.NO (TGS-NOPEC Geophysical Co.) -- TGS and Viridien announce launch of Laconia phase III OBN survey in the Gulf of America

      • KAMBI.SS (Kambi Group) -- initiates SEK 165M share repurchase program

      • AIR.FP (Airbus SE) -- STARLUX Airlines signs a firm order for the purchase of ten additional A350-1000 aircraft (18-Jun)

      • NESN.SW (Nestle) -- chair Paul Bulcke to not stand for re-election

      • AVOL.SW (Avolta) -- announces 9-year contract extension with Grupo Aeroportuario Centro Norte (OMA)

  • Key rating changes

    • Upgrades

      • MTX.GR (MTU Aero Engines) -- to buy from hold at Deutsche Bank

      • ETL.FP (Eutelsat Communications) -- to neutral from underperform at Oddo

    • Downgrades

      • PGHN.SW (Partners Group Holding) -- to neutral from buy at Goldman Sachs

      • AKSO.NO (Aker Solutions) -- to sell from hold at DNB Carnegie

    • Initiations

      • TKA.AV (Telekom Austria) -- hold at Deutsche Bank

      • SAA.LN (M&C Saatchi) -- buy at Berenberg

  • Data

    • Nikkei (0.89%) to 38540.54

    • Hang Seng (1.70%) to 23308.79

    • Shanghai Composite (0.66%) to 3366.37

    • S&P futures (12.8) vs prior close of 6034.3

    • €-$ (0.0023) or (0.20%) to 1.1461

    • $-¥ +0.03 or +0.02% to 145.16

    • €-¥ (0.27) or (0.16%) to 166.34

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE